35th week of 2009 patent applcation highlights part 36 |
Patent application number | Title | Published |
20090214492 | ISOLATED STROMAL CELLS FOR USE IN THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM - Methods of treating a human patient having a disease, disorder or condition of the central nervous system are disclosed. The methods include obtaining a bone marrow sample from a human donor, isolating stromal cells from the bone marrow sample, and administering the isolated stromal cells to the central nervous system of the human patient, wherein the presence of the isolated stromal cells in the brain effects treatment of the disease, disorder or condition. Stromal cells which are isolated may be cultured in vitro, they may be genetically engineered to produce therapeutic compounds, and/or they may be pre-differentiated prior to administration into the central nervous system. | 2009-08-27 |
20090214493 | Cardiac Muscle Regeneration Using Mesenchymal Stem Cells - Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 2009-08-27 |
20090214494 | Cancer Vaccines and Therapeutic Methods - Compositions and methods of producing improved cancer vaccines are described. In addition, methods of identifying tumor associated antigens are also described. | 2009-08-27 |
20090214495 | VASCULAR ENDOTHELIAL GROWTH FACTOR-D (VEGF)-D AND FUNCTIONALLY FRAGMENTS THEREOF FOR BONE REPAIRING - The invention refers to use of VEGF-D or fragments thereof for the preparation of a medicament for therapy and/or prevention of bone diseases, to compositions comprising the same, vectors for gene therapy, to cells expressing VEGF-D. | 2009-08-27 |
20090214496 | BMX/ETK TYROSINE KINASE GENE THERAPY MATERIALS AND METHODS - The present invention relates to materials and methods for the treatment of arterial diseases having impaired arteriogenesis and angiogenesis. More particularly, the invention provides materials and methods for treating arterial disease using a gene therapy vector expressing Bmx tyrosine kinase. | 2009-08-27 |
20090214497 | Novel Acid Tolerant Lactobacillus Sakei Probio-65 with the Ability of Growth Suppression of Pathogenic Microorganisms and the Anti-Allergic Effect - Disclosed are a novel tactic acid bacterium, | 2009-08-27 |
20090214498 | ANTIMICROBIAL PEPTIDES AND BACTERIAL STRAINS THAT PRODUCE THEM - The present invention relates generally to the field of health promoting agents, in particular antimicrobial agents and provides antimicrobial peptides and bacterial strains that provide the antimicrobial peptides. In one aspect, the invention provides a biologically pure culture of | 2009-08-27 |
20090214499 | Feline probiotic bifidobacteria - According to the invention there is provided a strain of lactic acid bacteria of the genus | 2009-08-27 |
20090214500 | PREVENTION AND TREATMENT OF OSTEOCHONDROSIS IN ANIMALS AND HUMANS - The present invention relates to compositions and methods for preventing and treating osteochondrosis by administration of supplemental boron containing compounds to animals and humans. The supplemental boron containing compounds are provided in animal feed compositions or as supplements for animal feed. Also provided by this invention are animal feed compositions that are supplemented with boron containing compounds and which have reduced phosphorus content. The invention also provides a method for treating or preventing osteochondrosis in animals or humans by the administration of supplemental boron containing compounds. The invention also provides a method for decreasing the amount of phosphorus excreted by an animal, a method of increasing the efficiency of absorption of phosphorus by an animal, a method of reducing environmental phosphorus pollution by administering supplemental boron to the animal. The invention also provides a method of reducing pre-weaning mortality in an animal by feeding pregnant, nursing or lactating animals by administering supplemental boron containing compounds. | 2009-08-27 |
20090214501 | GEL-BASED COSMETIC AND WOUND-HEALING FORMULATION AND METHOD - Disclosed are gel-based cosmetic and wound-healing formulations, methods for making said formulations, and a method for simultaneously treating and concealing injuries to human skin. In one exemplary embodiment, the cosmetic and wound-healing formulation comprises live yeast cell extract, pigment, and a gel. | 2009-08-27 |
20090214502 | GREEN MOLD INHIBITOR - The present invention provides a novel biocontrol agent for the prevention and/or reduction of mold during mushroom production. In particular, the invention utilizes | 2009-08-27 |
20090214503 | NEW BACILLUS SUBTILIS STRAIN ATCC.RTM. PTA-8805, BIOPRODUCTS CONTAINING SAID STRAIN AND USE OF THE SAME TO CONTROL THE FUNGUS RHIZOCTONIA SOLANI, AN IMPORTANT PLANT PATHOGEN THAT ATTACKS ECONOMICALLY RELEVANT CROPS - The present application is directed to a new | 2009-08-27 |
20090214504 | Methods and Compositions for Topical Treatment of Medical Conditions Including Wounds and Inflammation - A method for treating a patient suffering from a wound, ulcer, or inflammation includes providing a topical formulation comprising a carrier and a combination of active ingredients that includes at least one retinoid and at least one blood vessel dilator, and applying the topical formulation to the skin of the patient to cause healing, accelerated healing or prevention of the wound, ulcer or inflammation. Additional active ingredients may include a promoter of mitochondrial function or an antioxidant. | 2009-08-27 |
20090214505 | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof - Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided. | 2009-08-27 |
20090214506 | Use of TFPI to Treat Severe Bacterial Infections - Methods for prophylactically or therapeutically treating a patient at risk of developing or diagnosed as having a severe bacterial infection involving administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog at low doses to avoid adverse side effects. | 2009-08-27 |
20090214507 | METHOD OF TREATING PREVENTING, INHIBITING OR REDUCING DAMAGE TO CARDIAC TISSUE - A method of treatment for treating, preventing, inhibiting or reducing damage to coronary tissue includes inducing at least one of a physiological function selected from: up-regulation of or increasing ILK activity in the coronary tissue, up-regulation of or increasing Akt activity in the coronary tissue, down-regulation of or reducing cardiomyocyte cell death in the coronary tissue and hibernation of cardiomyocytes in the coronary tissue. An induction agent capable of inducing such physiological function in a subject is administered to a subject in need of such treatment. | 2009-08-27 |
20090214508 | VEGF-ACTIVATED FAS LIGANDS - The present invention provides fusion proteins comprising an extracellular domain of a VEGF receptor and a death ligand. The fusion proteins bind to VEGF and to death receptors on tumor cells thereby inhibiting VEGF activation of VEGF receptors and inducing apoptosis in the tumor cells. Fusion proteins of the present invention are useful for inducing apoptosis and cytotoxic effects in cells, treating cancer and diseases or disorders related to unregulated angiogenesis and/or vasculogenesis. Thus, this invention further provides methods for treating angiogenesis related diseases using the fusion proteins, polynucleotides encoding the fusion proteins, vectors containing the polynucleotides, pharmaceutical compositions and kits containing the fusion proteins or the polynucleotides encoding the fusion proteins. | 2009-08-27 |
20090214509 | Novel Bacillus Thuringiensis Gene with Lepidopteran Activity - The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of | 2009-08-27 |
20090214510 | Broad Spectrum Antiviral Compositions - The instant invention provides compositions and methods for the treatment of viral infections caused by enveloped viruses comprising phospholipase nucleic acid molecules or polypeptides, or fusion molecules comprising phospholipase molecules or functional fragments thereof. | 2009-08-27 |
20090214511 | DIGESTIBLE COMPOSITIONS OF INULIN FOR MANAGING BLOOD GLUCOSE LEVELS - Digestible compositions of inulin for managing blood glucose levels in a patient are disclosed. The compositions can include an inulin, a sucrose and an amylase, wherein the inulin is configured to lower blood glucose in the patient and wherein the sucrose is presented in sufficient amount to at least partially counteract the blood glucose lowering effect of the inulin. Several embodiments disclosed in the present application include a vegetable mixture comprising burdock root, carrots and daikon radish and additional constituents such as dimethyl sulfoxide, lentinan and D-eritadenine. Additionally, methods of preparing a digestible composition of inulin are also disclosed. | 2009-08-27 |
20090214512 | METHODS OF TREATING SKIN DISEASE, SCALP DISEASE, SENSITIVE SKIN OR SUPPRESSING HAIR LOSS WITH MICROBUBBLE WASHING COMPOSITIONS - The present invention provides a microbubble washing composition for washing a human body or an animal, a microbubble washing method using the microbubble washing composition, and a microbubble washing apparatus suitable for carrying out the method are provided which are capable of safely removing sebum and old keratin adhering to the surfaces of the pores in a short period of time, keeping the skin clean for a long period of time, preventing an odor. Specifically, the present invention provides a microbubble washing composition for washing a human body or an animal including a protease and a lipase, a microbubble washing method for washing a human body or an animal including washing a human body or an animal using a washing liquid containing the washing composition and microbubbles, and a microbubble washing apparatus. | 2009-08-27 |
20090214513 | MAMMALIAN EXPRESSION SYSTEMS - The present invention features mammalian expression systems with improved production yields, and method of using these systems to produce desired proteins. In one embodiment, the expression systems of the present invention comprise genetically-engineered mammalian host cells cultured in a medium that contains an effective amount of heparin or heparin-like molecules. The presence of heparin or heparin-like molecules significantly increases protein production by the cultured cells. The present invention also features the use of constitutively-active components of FGFR-I-mediated signal transduction pathways to improve protein production by cultured mammalian cells. Co-expression of such a component with a protein of interest markedly increases the production yield of the protein of interest. | 2009-08-27 |
20090214514 | GUS3 NEUROPEPTIDES FOR REGULATING HYPOTHALAMIC FUNCTION - The present invention relates to use of GUS3 neuropeptides or functional variants in a medicament. The invention furthermore relates to specific medical uses of such neuropeptides, for regulating hypothalamic function. | 2009-08-27 |
20090214515 | METHODS OF PREPARATION OF RECOMBINANT FORMS OF HUMAN BETA-AMYLOID PROTEIN AND USES OF THESE PROTEINS - The subject invention relates to the cloning, expression and isolation of recombinant forms of beta-amyloid protein containing a N-terminal methionine (or one or more amino acids) as well as to methods of using this recombinant protein in the production of therapeutic antibodies, in the identification of therapeutic small molecules, and in the performance of diagnostic assays. | 2009-08-27 |
20090214516 | Inhibitors of Reglll Proteins as Asthma Therapeutics - Methods of screening for agents for treating asthma are provided. The methods involve screening for agents that decrease the production or activity of a RegIII protein that has been discovered herein to play a role in producing the symptoms and pathological complications involved in asthma. Methods of treating asthma, as well as screening for and treating with inhibitors of a RegIII protein are also provided. | 2009-08-27 |
20090214517 | Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease - Microarray analysis, confirmed by RT-PCT, demonstrated that mRNA derived from cancerous tissues hybridized specifically and preferentially to human nectin 4, semaphorin 4b, IgSF9, and KIAA0152. Microarray analysis also demonstrated that RNA from malignant bladder, pancreas, and stomach tissue hybridized specifically to human nectin 4, semaphorin 4b, IgSF9, and KIAA0152, all of which are transmembrane proteins that provide a therapeutic target for treating cancer. Modulators of nectin 4, semaphorin 4b, IgSF9, and KIAA0152 are provided for the diagnosis and treatment of proliferative disorders such as cancer and psoriasis. The invention further provides methods of treating cancer with therapeutic agents directed toward nectin 4, semaphorin 4b, IgSF9, and KIAA0152. | 2009-08-27 |
20090214518 | Methods and compositions for treating solid tumors and enhancing tumor vaccines - The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of ETRB, ET-1, ICAM-1, or another protein found herein to play a role in homing of T cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of T cells to a solid tumor, or a nucleotide molecule encoding same. | 2009-08-27 |
20090214519 | Compositions and Methods for Treating Inflammation - The present invention relates to compositions to treat inflammation (LIGHT pathway) related disorders, and specifically liver inflammation or hepatitis. The invention also relates to methods treating LIGHT pathway related disorders. The invention further relates to kits for treating LIGHT pathway related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating LIGHT pathway related disorders in a subject. | 2009-08-27 |
20090214520 | Soluble CLCA-1 and antagonists to CLCA-1 - The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid. | 2009-08-27 |
20090214521 | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer - The present invention pertains to the use of BMP-2, which is overexpressed in most common cancers, as 1) a target for cancer treatment therapies and 2) a means to diagnose cancer. The therapeutic component of this invention involves administering to a patient a composition that inhibits bone morphogenetic-2 activity. Such inhibition may be accomplished by ligands or antibodies that bind to BMP-2 or BMP-2 receptors. It may also be achieved by preventing the processing of pro-BMP-2, or blocking transcription or replication of BMP-2 DNA or translation of BMP-2 mRNA. The diagnostic component of the invention involves measuring the BMP-2 level in biological samples from both a patient and a subject and comparing those levels. Elevated levels of BMP-2 in the patient compared to the non-cancerous subject indicate cancer. | 2009-08-27 |
20090214522 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF - The present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process for preparing highly concentrated antibody compositions, and highly concentrated antibody products. | 2009-08-27 |
20090214523 | Novel anti-IL13 antibodies and uses thereof - The present invention relates to anti-IL13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis. | 2009-08-27 |
20090214524 | Methods and compositions for regulating cell cycle checkpoints - The invention relates to regulation of cell cycle checkpoints, and the application of such regulation in the treatment of disease, particularly cancer. | 2009-08-27 |
20090214525 | Novel anti-igf-ir antibodies and uses thereof - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or anti-VEGF antibodies and/or antibodies directed against other growth factors involved in tumor progression or metastasis and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 2009-08-27 |
20090214526 | Optimized Fc Variants and Methods for Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 2009-08-27 |
20090214527 | Combination Of Anti-Madcam Antibody And Antifibrotic Caspase Inhibitor To Treat Liver Fibrosis - The invention relates to a new combination of an anti-MAdCAM antibody with an anti-fibrotic agent, such as a protease inhibitor, preferably a caspase inhibitor. The invention also relates to pharmaceutical compositions comprising the combination of the invention, and the use of the combination for the treatment of liver fibrosis. | 2009-08-27 |
20090214528 | HOST CELL LINES FOR PRODUCTION OF ANTIBODY CONSTANT REGION WITH ENHANCED EFFECTOR FUNCTION - Host cell lines for biopharmaceutical production of antibodies, antibody fragments or antibody-derived fusion proteins are selected as having the capability of inducing improved cellular effector functions, e.g., Fc-medicated effector functions. The host cells are derived from the rat myeloma cell line YB2/0 and are adapted to growth in chemically-defined medium. | 2009-08-27 |
20090214529 | KINESIN INHIBITORS - This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat a kinesin Eg5 protein-mediated disorder. | 2009-08-27 |
20090214530 | MODIFIED CpG OLIGODEOXYNUCLEOTIDE WITH IMPROVED IMMUNOREGULATORY FUNCTION - The present invention relates to a modified CpG oligodeoxynucleotide (ODN) which is prepared by coupling a consecutive sequence of deoxyribothymine (dT) to the 3′-terminus of CpG ODN having immunoregularory function, thereby improving immunoactivity of splenocytes, macrophages and peripheral mononuclear cells, and therefore, can be effectively used as a vaccine adjuvant for preventing and treating hepatitis B or an anticancer agent. Since the phosphorothioate CpG ODN having the consecutive sequence of dT at its 3′-terminus shows high activity inducing Th-1 immune response and does not elicit in vivo toxicity with guaranteeing its safety, it can be effectively used as a vaccine adjuvant. | 2009-08-27 |
20090214531 | Methods and Compositions for Treating and Preventing Bacterial Infections - The invention features methods and compositions for treating or preventing Gram-negative bacterial infections. | 2009-08-27 |
20090214532 | ANKTM1, A Cold-Activated TRP-Like Channel Expressed in Nociceptive Neurons - The methods and compositions of the invention are based on a method for measuring nociceptive responses in vertebrates, including humans and other mammals utilizing a newly discovered thermoreceptor belonging to the Transient Receptor Potential (TRP) family of non-selective cation channels that participates in thermosensation and pain. This receptor, designated ANKTM1, is associated with nociceptive pain, such as hyperalgesia. Accordingly, the invention provides isolated polypeptides and polynucleotides associated with nociception as well as methods for identifying or screening agents that modulate nociception. | 2009-08-27 |
20090214533 | METHODS FOR CONVERTING OR INDUCING PROTECTIVE IMMUNITY - The invention is based in part on the finding that suppressing regulatory T cell function is needed in order to convert passive immunity into active antigen-specific immunity. Generally, the methods of the invention comprise at least the combination of: (1) increasing the amount of immune complexes in the subject, wherein the immune complex comprises a target antigen and a immunoglobulin molecule comprising (i) a variable region specific to the target antigen and (ii) a Fc receptor binding region; and (2) inhibiting regulatory T cell function or decreasing/depleting the regulatory T cell population in the subject. | 2009-08-27 |
20090214534 | Bispecific Domain Antibodies Targeting Serum Albumin And GLP-1 Or PYY - Drug fusions and conjugates that contain an incretin therapeutic or diagnostic agent that is fused or conjugated to an antigen-binding fragment of an antibody that binds serum albumin. The conjugates and fusion have a longer in vivo half life in comparison with the unconjugated or unfused therapeutic or diagnostic agent. | 2009-08-27 |
20090214535 | Pharmaceutical Compositions Containing sc(Fv)2 - The present inventor discovered stabilizing agents/stabilizing conditions for suppressing isomerization reactions of sc(Fv)2. It was also discovered that the above-mentioned isomerization reactions can be suppressed through use of freeze-dried formulations. As disclosed herein, by applying the discovered stabilizing agents/stabilizing conditions or the freeze-dried formulation, the isomerization reaction of an sc(Fv)2-type molecule from the bivalent scFv type to the single chain diabody type, and/or the isomerization reaction from a single chain diabody type to a bivalent scFv type can be suppressed in both directions or one direction. | 2009-08-27 |
20090214536 | CACNA1E in Cancer Diagnosis, Detection and Treatment - This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the CACNA1E gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the CACNA1E gene. | 2009-08-27 |
20090214537 | Serum Resistance Factors of Gram Positive Bacteria - A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection. | 2009-08-27 |
20090214538 | USE OF COMPLEMENT INHIBITORS TO TREAT OCULAR DISEASES - The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9, or C5b-9. | 2009-08-27 |
20090214539 | B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES - The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules. | 2009-08-27 |
20090214540 | Protein involved in cancer - The present invention relates to new uses of PSK-1 in the diagnosis, screening, treatment and prophylaxis of ovarian and lung cancer. The invention also provides compositions comprising PSK-1, including vaccines, antibodies that are immunospecific for PSK-1 and agents which interact with or modulate the expression or activity of PSK-1 or which modulate the expression of the nucleic acid which codes for PSK-1. | 2009-08-27 |
20090214541 | Combination Therapy Using Anti-EGFR and Anti-HER2 Antibodies - The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer. | 2009-08-27 |
20090214542 | Novel therapeutic targets in cancer - The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer. | 2009-08-27 |
20090214543 | METHODS FOR TREATING CANCER USING AN IMMUNO-TOXIN COMPRISING AN EXOTOXIN A MOIETY HAVING A FURIN CLEAVAGE SITE REPLACED WITH A CANCER ASSOCIATED PROTEASE SITE CLEAVED BY MMP-2 OR MMP-9 - The present invention provides a modified toxin having an ETA moiety that has the furin site replaced with a cancer-associated protease site. The present invention also provides modified immunotoxins having a ligand that binds to a cancer cell attached to an ETA moiety that has the furin site replaced with a cancer-associated protease site. Also provided are a method of inhibiting or destroying mammalian cancer cells using the immunotoxins of the invention and pharmaceutical compositions for treating human cancer. | 2009-08-27 |
20090214544 | Method of treating cd30 positive lymphomas - Methods for treating lymphomas characterized by expression of CD30 using anti-CD30 antibodies and steroids in combination are disclosed. | 2009-08-27 |
20090214545 | Method of Treating or Preventing an IL-1 Related Disease or Condition - Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency. | 2009-08-27 |
20090214546 | Novel therapeutic targets in cancer - The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer. | 2009-08-27 |
20090214547 | BINDING MEMBER TOWARDS PNEUMOLYSIN - The present invention relates to an anti-haemolytic binding member comprising at least one binding domain capable of specifically binding Pneumolysin, in particular to a binding member having at least two biding domains, to the use of said binding members in diagnostic methods as well as for treatment. In a preferred embodiment the binding member is an antibody, such as a human antibody, or a fragment thereof, and it may also be a bispecific antibody. | 2009-08-27 |
20090214548 | TGR3-Like Protein Receptor - There are provided proteins containing a domain corresponding to the C-terminal half of a ZP domain similar to that identified in TGF-beta Receptor III and the use of the proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of diseases. In particular, the present invention relates to the use of the disclosed proteins for modulating the activity of proteins belonging to the TGF-beta superfamily. | 2009-08-27 |
20090214549 | Antigenic Epitopes Of Inteleukin-21, Related Antibodies And Their Use In Medical Field - The present invention relates to antigenic epitopes of interleukin-21, related antibodies and their use in medical field, in particular for the treatment of immune-inflammatory diseases characterized by an enhanced production and/or activity of IL-21, such as for example chronic inflammatory bowel diseases (IBD), celiac disease and psoriasis. | 2009-08-27 |
20090214550 | Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy - The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed. | 2009-08-27 |
20090214551 | High Affinity Hiv T Cell Receptors - The present invention provides TCRs having an affinity (K | 2009-08-27 |
20090214553 | Complete human monoclonal IgG4lambda specific for CTLA-4 and uses thereof for detection of soluble CTLA-4 and isolation of regulatory cells - The present invention provides a CTLA-4 non-blocking agent of a complete human antibody nature, thus is non-immunogenic in a human. The immunoassay method using such a non-blocking agent measures the CTLA-4 content in a sample of a human subject. The present invention further provides a novel method for isolating human regulatory T cells. The resultant enriched and depleted cellular populations are useful in treating or ameliorating of human diseases. | 2009-08-27 |
20090214554 | TRUNCATED MEMAPSIN 2 COMPOSITIONS AND TREATMENTS - The present invention provides novel methods of reducing memapsin 2 β-secretase activity in a subject, decreasing levels of β-amyloid peptide in the brain of a subject, treating Alzheimer's disease and/or reducing the size and/or number of β-amyloid plaques in the brain of a subject. The methods may include the step of administering an effective amount of truncated memapsin 2 protein, anti-truncated memapsin 2 antibody, and/or nucleic acid encoding a truncated memapsin 2 protein or anti-truncated memapsin 2 antibody. The present invention also provides related pharmaceutical compositions and uses thereof. | 2009-08-27 |
20090214555 | Proteoglycan Splice Variants as Therapeutics and Diagnostics for Amyloid Diseases - The identification of novel Syndecan-2 splice variants and their use in the diagnosis and therapeutic intervention of Alzheimer's disease and other amyloid diseases. In addition the use of new animal models expressing or devoid of syndecan-2 splice variants to effectively screen and identify potential therapeutic compounds for Alzheimer's disease. | 2009-08-27 |
20090214556 | ANTIBODIES AND RELATED MOLECULES THAT BIND TO 161P2F10B PROTEINS - Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization. | 2009-08-27 |
20090214557 | BIOLOGICALLY ACTIVE ANTIBODIES RECOGNIZING A CELL SURFACE MOLECULE SELECTIVELY EXPRESSED ON LIVING MOUSE NATURAL TYPE ONE (I) INTERFERON PRODUCING CELLS - An isolated and characterized monoclonal antibody (“440 | 2009-08-27 |
20090214558 | NOVEL MAdCAM ANTIBODIES - The invention provides new, improved anti-MAdCAM antibodies. Uses of these antibodies in medicine are also included, in particular for the treatment of inflammatory conditions such as inflammatory bowel disease. | 2009-08-27 |
20090214559 | Therapeutic Human Anti-IL-1R1 Monoclonal Antibody - Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described. | 2009-08-27 |
20090214560 | BINDING MOLECULES TO THE HUMAN OX40 RECEPTOR - The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions. | 2009-08-27 |
20090214561 | Treatment method - The invention provides methods of treating autoimmune diseases by administration of a complete therapeutically effective amount of a CD20 specific antagonist as a single intravenous infusion. Retreatment may follow by the administration of a complete therapeutically effective amount of the CD20 specific antagonist by a single intravenous infusion, 4 to 6 months after the first administration. The CD20 specific antagonist preferably is a CD20 specific antibody, and the autoimmune disease preferably is rheumatoid arthritis. | 2009-08-27 |
20090214562 | Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection - The present invention encompasses a therapeutic combination composition of a β-glucan EGF receptor antagonist. This therapeutic combination composition is useful for the treatment of diseases including proliferative disorders and immune dysfunction. | 2009-08-27 |
20090214563 | TREATMENT FOR ANTIPHOSPHOLIPID-SYNDROME-RELATED PREGNANCY COMPLICATIONS - The present application provides compositions and methods for treating antiphospholipid-syndrome-related pregnancy complications with tissue factor antagonists. | 2009-08-27 |
20090214564 | ANTI-EPHRINB2 ANTIBODIES AND METHODS USING SAME - The invention provides anti-EphrinB2 antibodies, and compositions comprising and methods of using these antibodies. | 2009-08-27 |
20090214565 | Anti-Interferon Alpha Monoclonal Antibodies and Methods For Use - The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease. | 2009-08-27 |
20090214566 | Protective anti-glucan antibodies with preference for beta-1,3- glucans - Anti-β-1,3-glucan antibodies have been found to be protective against systemic fungal infection with | 2009-08-27 |
20090214567 | Immunoglobulin Fraction and Process Therefor - The invention relates to the production of compositions containing IgA for use as a food additive. More specifically, it relates to a process to prepare an IgA-enriched milk product extract composition and to such compositions. | 2009-08-27 |
20090214568 | Method of Treating or Preventing an IL-1 Related Disease or Condition - Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency. | 2009-08-27 |
20090214569 | Use of HIV envelope/CD4 complexes for the generation antibodies - The instant invention provides antibodies, vaccines, and immunogenic compositions, for the treatment and prevention of HIV infection. The invention further provides kits comprising the antibodies, vaccines and immunogenic compositions, of the invention. | 2009-08-27 |
20090214570 | METHODS AND COMPOSITIONS FOR IMMUNIZING AGAINST CHLAMYDIA INFECTION - The present invention relates, in part, to methods and compositions for immunizing against infection by | 2009-08-27 |
20090214571 | COLON CANCER RELATED GENE TOM34 - Objective methods for detecting and diagnosing colon cancer are described herein. In one embodiment, the diagnostic method involves determining the expression level of TOM34 that discriminates between colon cancer cells and normal cells. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of colon cancer, methods of treating colon cancer and method for vaccinating a subject against colon cancer. | 2009-08-27 |
20090214572 | Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders - The invention features methods and compositions for treating and preventing angiogenic disorders and endothelial cells disorders using HspA12B antagonist and HspA12B agonist compounds, respectively. | 2009-08-27 |
20090214573 | MODULATION OF BNE DEVELOPMENT - Methods and compositions for modulating bone development are described. | 2009-08-27 |
20090214574 | Anti-cd16 binding molecules - The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. FcγRIIIA), and in particular binding molecules that specifically bind the A form FcγRIII but do not bind to the B form of FcγRIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells. | 2009-08-27 |
20090214575 | Annexin II and uses thereof - The present invention relates to the field of diagnosis and treatment of neurodegenerative diseases, ischemic events, and central nervous system injury, and provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. | 2009-08-27 |
20090214576 | TYROSINE KINASE INHIBITOR COMPOSITIONS AND METHODS FOR MANUFACTURING AND USING THEM IN THE TREATMENT OF DISEASE - The invention is the method of using the soluble modified receptor erbB3 to treat breast cancer by competitively inhibiting ligands, such as heregulin, from binding to erbB3 tyrosine kinase receptors on cell surfaces. | 2009-08-27 |
20090214577 | Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof - DNA plasmids containing sequences coding for different fragments of 185 | 2009-08-27 |
20090214578 | Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone - Immunostimulatory single-stranded oligoribonucleotides (ssORN) with phosphodiester backbones induce TLR7-independent and MyD88-dependent immune activation. These immunostimulatory ssORN are useful to induce a ThI-like immune response in a subject, to induce an antigen-specific immune response in a subject, and to treat a subject having a cancer, an infectious disease, an allergic condition, or asthma. | 2009-08-27 |
20090214579 | PROMOTER FOR INTRODUCING A GENE INTO A LYMPHOCYTE OR BLOOD CELL AND APPLICATION THEREOF - It is intended to provide a promoter for inducing expression selectively and strongly in an immunocompetent cell and/or a blood cell such as a lymphocyte. In the invention, the object was achieved by finding that HHV6 MIE promoter, HHV7 MIE promoter and HHV7 U95 promoter unexpectedly induce a specific expression in an immunocompetent cell and/or a blood cell such as a T lymphocyte. By utilizing the promoters, a selective delivery of a DNA vaccine or the like can be realized. | 2009-08-27 |
20090214580 | Peptide mixtures with immunomodulatory activity - The present invention is related to complex peptide mixtures with immunomodulatory effects and methods for their use. The invention is further directed toward treatments of diseases through the modulation of the immune system with complex peptide mixtures. The invention is also directed to methods for improving the characteristics of complex peptide mixtures. | 2009-08-27 |
20090214581 | EPITOPE PEPTIDES DERIVED FROM VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 AND VACCINES CONTAINING THESE PEPTIDES - The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines. | 2009-08-27 |
20090214582 | METHODS FOR IDENTIFYING AN EPITOPE OF A POLYPEPTIDE, CHLAMYDIAL ANTIGENIC POLYPEPTIDES IDENTIFIED THEREBY, AND METHODS OF USE THEREOF - The present invention provides a method of classifying an epitope displayed by a polypeptide; a method of determining the presence of an epitope on a polypeptide encoded by a test nucleotide sequence; and a method of generating a nucleotide sequence encoding a polypeptide that exhibits a selected epitope. The present invention provides antigenic polypeptides that display selected epitope(s); chimeric macromolecules comprising such polypeptides; and compositions comprising the antigenic polypeptides or chimeric macromolecules. The present invention further provides methods of inducing an immune response to a | 2009-08-27 |
20090214583 | Epitope-enhancement of a human cd4 hiv epitope - Virus-specific CD4 | 2009-08-27 |
20090214584 | Characterization of novel lpxtg-containing proteins of staphylococcus epidermidis - The present invention is directed toward isolated | 2009-08-27 |
20090214585 | Medicament, Particularly an Anti-Cancer Medicament, for Treatment Using Immunotherapy, Particularly Autologous - The invention relates to a medicament characterized in that it comprises at least one solid biocompatible support, preferably in powder form, on which at least one active substance, preferably selected among biological materials and/or biological molecules, is adsorbed or on which it is to be adsorbed, preferably without requiring a coupling agent. Said solid biocompatible support is capable of purifying the active substance. The invention relates to also relates to a method for preparing a medicament of the aforementioned type, this method essentially consisting of placing at least one solid biocompatible support, preferably in powder form, in contact with at least one active substance, preferably selected among biological materials and/or biological molecules, in such a manner that the active substance is reversibly adsorbed and without denaturing on the support. | 2009-08-27 |
20090214586 | Combination Vaccines With Whole Cell Pertussis Antigen - Vaccines have been studied that comprise (a) D-T-Pw-HepB-Hib antigens and (b) one or more meningococcal conjugate antigens. A number of improvements and variations of these vaccines have been discovered. The vaccines can be prepared extemporaneously at the time of use by mixing together two components: (a) a first component comprising D, T, wP and HBsAg antigens; and (b) a second component comprising a Hib conjugate and one or more meningococcal conjugates. | 2009-08-27 |
20090214587 | Recombinant virus and use thereof - The present invention provides a recombinant virus which is efficacious and highly safe in preventing the onset of SARS infection and a vaccine for SARS coronavirus containing the same. The recombinant virus of the invention can express a SARS coronavirus gene. | 2009-08-27 |
20090214588 | Vaccines against aids comprising cmv/r-nucleic acid constructs - The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided. | 2009-08-27 |
20090214589 | Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine - Use of a recombinant lentiviral vector comprising a polynucleotide fragment encoding at least one protein of a virus of the family Flaviviridae or an immunogenic peptide of at least 8 amino acids of said protein, for preparing a pharmaceutical composition intended for the prevention and/or the treatment of a Flaviviridae infection in a sensitive species. | 2009-08-27 |
20090214590 | Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof - The present invention provides novel virus vaccines with augmented, e.g., enhanced and/or extended immunogenicity. The virus vaccines of the invention comprise an envelope-bound immunomodulatory protein, e.g., a cytokine, chemokine or costimulatory molecule. The immunomodulatory protein serves as an adjuvant to augment, e.g., enhance or extend the immunogenicity of the virus vaccine, thereby augmenting, e.g., enhancing or extending immune response to the virus when administered to a subject. | 2009-08-27 |
20090214591 | Immunogens for Vaccines Against Antigenically Variable Pathogens and Diseases - The present invention provides compositions and methods for the therapeutic and/or prophylactic treatment of pathogen infections and/or disease states. The compositions may comprise variable epitope libraries (VELs), containing antigenic epitopes with one or more amino acid substitutions in the native epitope sequence. In preferred embodiments, the substituted amino acid may be replaced with each of the 19 other naturally occurring amino acids. In more preferred embodiments, multiple amino acid residues may be substituted. Such compositions and methods may be of use for production of vaccines against pathogens or diseases that show a high degree of genetic variability. | 2009-08-27 |
20090214592 | Adjuvant composition comprising aluminium phosphate and 3D-MPL - An immunogenic composition comprising: (i) an antigen; (ii) an aluminum phosphate adjuvant; and (iii) a 3-O-deacylated monophosphoryl lipid A adjuvant. Components (ii) and (iii) can also be used as a separate adjuvant system. Various features of the compositions are disclosed, including that at least 50% of the 3-O-deacylated monophosphoryl lipid A adjuvant should be adsorbed to the aluminum phosphate adjuvant. The adjuvant mixture is particularly useful with hepatitis B virus surface antigen. | 2009-08-27 |